TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$175 Million

Sage Therapeutics

Follow-on Offering

Lead Manager, September 2016

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-altering central nervous system, or CNS, disorders, where there are no approved therapies or existing therapies are inadequate. The Company has a portfolio of product candidates with a current focus on modulating two critical CNS receptor systems, GABA and NMDA.